Infinity Pharmaceuticals has gained access to Intellikine's portfolio of phosphoinositide 3-kinase-δ (PI3Kδ) and PI3Kγ inhibitors for inflammation and oncology indications through an exclusive ...
For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes compared with tofacitinib.
Our updated analyses presented at SABCS show STX-478’s low dose modification rates and increased response rate at higher doses, reflecting its high level of pathway inhibition. These studies ...